Tirzepatide
Tirzepatide is a dual incretin receptor agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is currently at the forefront of advanced research in metabolic and endocrine science due to its synergistic action and potential for superior glycemic control.
Price range: $43.99 through $104.99
-
Official retailer
-
Quality guaranteed
-
Within 2 Days Delivery
-
99% Purified
Tirzepatide is a novel dual agonist of the GLP-1 and GIP receptors, engineered to provide a synergistic approach to metabolic regulation. This next-generation incretin mimetic is at the forefront of research in obesity, insulin resistance, and type 2 diabetes. By targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, Tirzepatide enhances insulin secretion, suppresses glucagon, and modulates appetite and gastric motility.
โ Form: Lyophilized peptide
โ Purity: โฅ99%
โ Origin: Manufactured and tested in the USA
โ Certifications: Certificate of Analysis (COA) included with every order
Tirzepatide is a synthetic peptide designed to activate both GLP-1 and GIP receptors. Upon binding:
โ Stimulates insulin secretion in a glucose-dependent manner
โ Suppresses glucagon during hyperglycemia
โ Delays gastric emptying to promote satiety
โ Enhances adipocyte insulin sensitivity
โ Reduces appetite via central nervous system pathways
โ Dual incretin pathway investigation
โ Obesity and type 2 diabetes models
โ Appetite and food intake modulation
โ Insulin and glucagon dynamics
โ Cardiometabolic risk factor studies
โ Dual receptor targeting provides enhanced efficacy
โ Long-acting formulation mimics clinical pharmacokinetics
โ Validated in preclinical and translational models
โ High purity for consistent and reproducible outcomes
Each vial is:
โ Manufactured in a GMP-compliant U.S. facility
โ Accompanied by a Certificate of Analysis (COA)
โ Subjected to HPLC and mass spectrometry verification
โ Shipped from within the United States for quality control
โ Contents: 5mg of lyophilized Tirzepatide peptide
โ Appearance: White/off-white powder
โ Solubility: Sterile bacteriostatic water or acetic acid recommended
โ Storage: Store lyophilized vial at -20ยฐC; reconstituted solution stable up to 30 days when refrigerated
*For laboratory research use only. Not intended for human or veterinary use.*
โ This product is sold for research purposes only
โ Not for human consumption, injection, or diagnostic procedures
โ Must be handled by qualified professionals in accordance with institutional and governmental safety guidelines
Tirzepatide is a dual GIP and GLP-1 receptor agonist being researched for its effects on glucose regulation, insulin secretion, and body weight modulation. It mimics the incretin hormones to enhance insulin release and reduce appetite.
Tirzepatide activates both GIP and GLP-1 receptors. GIP enhances glucose-dependent insulin release, while GLP-1 delays gastric emptying, suppresses glucagon, and promotes satiety. The dual mechanism may offer synergistic benefits for metabolic research.
We provides Tirzepatide as a lyophilized powder in sterile vials for laboratory research only. It is synthesized and tested in certified U.S. laboratories.
No. Tirzepatide sold by Shop Peptides Direct is strictly for laboratory research use. It is not intended for human or veterinary consumption.
Keep lyophilized Tirzepatide at -20ยฐC in a dry, dark place. After reconstitution, store between 2โ8ยฐC and use according to your labโs stability guidelines.
Our Tirzepatide is >98% pure as verified by HPLC and Mass Spectrometry. Each order includes a certificate of analysis for full transparency.
Yes, we offer cold-chain shipping on request, though our standard packaging is designed to maintain stability during normal transit conditions.
Tirzepatide is often evaluated alongside other incretin-based peptides like Semaglutide or Cagrilintide. Any combinatory studies must follow research-approved protocols.
Navigate to our Lab Test Results page, select Tirzepatide, and provide your name and email to receive the lab documentation.
Our Tirzepatide is lab-tested, research-grade, and manufactured in the USA. Backed by fast fulfillment and excellent support, we prioritize quality and consistency.
Tirzepatide Dosage Protocol (5 mg, 10 mg, 15 mg Vials)
Quickstart Highlights
Tirzepatide is a 39โamino acid dual incretin receptor agonist that activates both GLPโ1 and GIP receptors, enhancing glucoseโdependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite[1][2]. Its ~5โday halfโlife allows convenient onceโweekly subcutaneous dosing[1]. Clinical trials demonstrate superior glycemic control and weight reduction compared to selective GLPโ1 agonists[3][4].
- 5 mg Vial Reconstitution: Add 2.0 mL bacteriostatic water โ 2.5 mg/mL concentration.
- 10 mg Vial Reconstitution: Add 2.0 mL bacteriostatic water โ 5.0 mg/mL concentration.
- 15 mg Vial Reconstitution: Add 2.0 mL bacteriostatic water โ 7.5 mg/mL concentration.
- Typical weekly range: 2.5โ15 mg once weekly (gradual 4โweek titration steps).
- Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL โ 25 mcg; at 5.0 mg/mL, 1 unit = 0.01 mL โ 50 mcg; at 7.5 mg/mL, 1 unit = 0.01 mL โ 75 mcg.
- Storage: Lyophilized: freeze at โ20 ยฐC (โ4 ยฐF); after reconstitution, refrigerate at 2โ8 ยฐC (35.6โ46.4 ยฐF); use within 28 days.
Dosing & Reconstitution Guide
Educational guide for all vial sizes - choose your optimal concentration
Standard / Gradual Approach (All Vial Sizes)
| Phase | Weekly Dose | 5 mg Vial (Units) | 10 mg Vial (Units) | 15 mg Vial (Units) |
|---|---|---|---|---|
| Weeks 1โ4 | 2.5 mg | 100 units (1.0 mL)* | 50 units (0.50 mL) | 33 units (0.33 mL) |
| Weeks 5โ8 | 5 mg | 100 units ร 2** | 100 units (1.0 mL) | 67 units (0.67 mL) |
| Weeks 9โ12 | 7.5 mg | 100 units ร 3** | 75 units ร 2** | 100 units (1.0 mL) |
| Weeks 13โ16 | 10 mg | 100 units ร 4** | 100 units ร 2** | 67 units ร 2** |
*Doses requiring >1.0 mL (100 units) may need split injections or larger syringes.
**Multiple injections may be required; rotate injection sites.
Route: Subcutaneous injection. Frequency: Once weekly on a consistent day.
Concentration Reference: 5 mg vial: 2.5 mg/mL; 10 mg vial: 5.0 mg/mL; 15 mg vial: 7.5 mg/mL. Choose vial size based on your weekly dose requirements - larger vials provide better efficiency for higher dose protocols.
Reconstitution Steps (All Vial Sizes)
- Draw appropriate volume of bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2โ8 ยฐC (35.6โ46.4 ยฐF), protected from light.
- Use within 28 days of reconstitution[6].
Supplies Needed
Plan based on an 8โ16 week protocol with gradual titration (onceโweekly dosing).
For All Vial Sizes
- Peptide Vials (Tirzepatide): Choose your preferred vial size (5 mg, 10 mg, or 15 mg).
- Insulin Syringes (Uโ100, 1 mL):
- 8 weeks: 8โ12 syringes (depending on vial size)
- 12 weeks: 12โ24 syringes (depending on vial size)
- 16 weeks: 16โ40 syringes (depending on vial size)
- Bacteriostatic Water (10 mL bottles): Volume depends on vial size and reconstitution.
- Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.
- Per week: 2 swabs (1 injection day)
- 8 weeks: 16 swabs โ recommend 1 ร 100โcount box
- 12 weeks: 24 swabs โ recommend 1 ร 100โcount box
- 16 weeks: 32 swabs โ recommend 1 ร 100โcount box
Protocol Overview
Concise summary of the onceโweekly regimen.
- Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation[2].
- Schedule: Weekly subcutaneous injection on the same day each week for 12โ16+ weeks.
- Dose Range: 2.5โ15 mg weekly with 4โweek titration intervals.
- Vial Options: 5 mg, 10 mg, or 15 mg vials with optimized reconstitution for each size.
- Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.
Dosing Protocol
Suggested weekly titration approach.
- Start: 2.5 mg once weekly for 4 weeks (initiation dose)[1].
- Escalate: Increase by 2.5 mg every 4 weeks as tolerated.
- Maintenance: 5โ15 mg weekly based on response and tolerability.
- Frequency: Once per week (subcutaneous), same day each week.
- Timing: Any time of day; with or without food; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at โ20 ยฐC (โ4 ยฐF) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2โ8 ยฐC (35.6โ46.4 ยฐF); do not freeze reconstituted solution[6].
- Shelf life: Use reconstituted solution within 28 days[6].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container[7].
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[8].
- For multiโinjection doses, use different sites for each injection on the same day.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document weekly dose, date, and injection site to maintain consistency.
- Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration helps minimize them[1].
- For โค10-unit (โค0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
How This Works
Tirzepatide is a novel dual agonist that simultaneously activates GLPโ1 (glucagonโlike peptideโ1) and GIP (glucoseโdependent insulinotropic polypeptide) receptors[1][2]. This dual mechanism enhances glucoseโdependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation[2]. The added GIP activity appears to synergistically amplify metabolic effects beyond GLPโ1 alone, contributing to superior weight reduction observed in clinical trials[3][4]. Its ~5โday halfโlife enables convenient onceโweekly administration[1].
Potential Benefits & Side Effects
Observations from clinical trials and published literature.
- Glycemic control: Significant HbA1c reductions in type 2 diabetes trials[4][9].
- Weight reduction: Clinical trials report substantial bodyโweight loss (up to ~11 kg more than GLPโ1 RA comparators over 26 weeks at higher doses)[3][4].
- Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies[9].
- Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation) โ typically mildโtoโmoderate and doseโdependent; gradual titration reduces incidence[1][5].
- Injectionโsite reactions: Occasional mild redness or irritation at subcutaneous injection sites.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, calorieโappropriate diet; reduced appetite may naturally decrease intake.
- Prioritize protein to preserve lean mass during weight loss.
- Combine resistance training and aerobic activity to support metabolic health.
- Stay hydrated, especially given potential gastrointestinal effects.
- Prioritize sleep and stress management to support adherence and recovery.
Injection Technique
General subcutaneous guidance from clinical bestโpractice resources[8][10].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45โ90ยฐ into subcutaneous tissue[8][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
- Rotate sites systematically (abdomen avoiding 2โinch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy[8].
- Dispose of needles and syringes in a sharps container immediately after use[7].
Recommended Source
We recommend Shop Peptides Direct for highโpurity Tirzepatide in all vial sizes (5 mg, 10 mg, 15 mg).
Why Shop Peptides Direct?
- Highโpurity, thirdโpartyโtested lots with batch COAs.
- Consistent, ISOโaligned handling and documentation.
- Reliable fulfillment to maintain coldโchain integrity.
- Multiple vial sizes to match different protocol needs.
Important Note
This content is for educational purposes only and is not medical advice. Tirzepatide is for research use only. Not for human consumption. Always consult with qualified professionals before starting any peptide research protocol.
References
-
StatPearls (NCBI Bookshelf) โ Farzam K, Patel P. Tirzepatide. StatPearls Publishing; 2024. Comprehensive overview of pharmacology, dosing, and clinical use.
-
Frontiers in Endocrinology โ Gallwitz B. GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes and obesity. Front Endocrinol. 2022;13:1004044.
-
The Lancet โ Frias JP, et al. Efficacy and safety of LY3298176 (tirzepatide), a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes (Phase 2 trial). Lancet. 2018;392(10160):2180-2193.
-
New England Journal of Medicine โ Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.
-
FDA Prescribing Information โ Mounjaro (tirzepatide) injection Prescribing Information. Eli Lilly and Company; 2022.
-
GobyMeds Pharmacy โ Does Compounded Tirzepatide Need To Be Refrigerated? Storage guidelines for reconstituted peptides.
-
CDC Injection Safety โ Preventing Unsafe Injection Practices. Guidelines for multi-dose vials and safe needle disposal.
-
MedlinePlus Medical Encyclopedia โ Subcutaneous (SQ) injections: Technique, site rotation, and best practices.
-
Mayo Clinic โ Tirzepatide (Subcutaneous route) โ Drugs and Supplements. Clinical overview and patient information.
-
CDC Vaccine Administration โ Subcutaneous injection technique: angle, site selection, and no aspiration guidance.
RELATED PRODUCTS
Semaglutide
5-Amino-1MQ
AOD-9604
View Certificate
KPV (ฮฑ-MSH fragment)
Thymosin Alpha-1
View Certificate
Reviews
There are no reviews yet.